86562-71-2

Usage

Functional Groups

Alcohol (-OH): Provides reactivity in organic synthesis.
Dioxolane Ring (1,3-dioxolane): A six-membered heterocyclic ring consisting of five carbon atoms and one oxygen atom, enhancing solubility and stability.
Methyl Groups (-CH3): Two methyl groups attached, contributing to steric effects and influencing properties like boiling point and solubility.
Isopropyl Group (-C3H7): Enhances solubility and can influence reactivity in chemical reactions.

Application

Solvent: Widely used as a solvent in various industries due to its ability to dissolve a wide range of substances.
Reagent: Can serve as a reagent in organic synthesis reactions, contributing to the formation of various organic compounds.

Versatility

The compound's structure and functional groups make it adaptable for numerous applications in different industries.

Properties

Solubility: Soluble in many organic solvents and water.
Boiling Point: The presence of functional groups affects the boiling point, typically higher than simpler alcohols due to increased molecular weight and complexity.
Stability: The dioxolane ring contributes to stability, making the compound less prone to decomposition under certain conditions.

Common Use Cases

Industrial solvents, pharmaceutical synthesis, organic chemistry reactions.

Upstream product

• 917-64-6 methyl magnesium iodide 
• 60456-21-5 methyl (4S)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 917-54-4 methyllithium 
• 110548-95-3 evoxine 
• 77-76-9 2,2-dimethoxy-propane 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 86547-26-4 Benzoesaeure-<(2S)-2,3-dihydroxy-3-methylbutyl>ester 
• 1093988-32-9 3-chloro-5-[(6-chloro-3-{[5-(4-{[(2S)-2,3-dihydroxy-3-methylbutyl]oxy}phenyl)-1,3,4-oxadiazol-2-yl]methyl}-2-fluorophenyl)oxy]benzonitrile 
• 1093988-65-8 methyl 2-methyl-4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)benzoate 
• 1093988-66-9 2-methyl-4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)benzohydrazide 
• 1093988-31-8 4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)benzohydrazide 
• 1093988-29-4 3-chloro-5-{[6-chloro-2-fluoro-3-({5-[4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)phenyl]-1,3,4-oxadiazol-2-yl}methyl)phenyl]oxy}benzonitrile 
• 1094342-09-2 3-chloro-5-[(6-chloro-3-{[5-(2-{[(2S)-2,3-dihydroxy-3-methylbutyl]oxy}-5-methyl-4-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl}-2-fluorophenyl)oxy]benzonitrile 
• 1094345-89-7 3-chloro-5-{[6-chloro-2-fluoro-3-({5-[5-methyl-2-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)-4-pyridinyl]-1,3,4-oxadiazol-2-yl}methyl)phenyl]oxy}benzonitrile 
• 1094345-86-4 N'-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}acetyl)-5-methyl-2-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)-4-pyridinecarbohydrazide 
• 1094345-84-2 N'-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}acetyl)-2-{[(2S)-2,3-dihydroxy-3-methylbutyl]oxy}-5-methyl-4-pyridinecarbohydrazide 
• 1094342-08-1 3-chloro-5-[(6-chloro-3-{[5-(6-{[(2S)-2,3-dihydroxy-3-methylbutyl]oxy}-4-methyl-3-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl}-2-fluorophenyl)oxy]benzonitrile 
• 1094342-07-0 3-chloro-5-{[6-chloro-2-fluoro-3-({5-[4-methyl-6-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)-3-pyridinyl]-1,3,4-oxadiazol-2-yl}methyl)phenyl]oxy}benzonitrile 
• 1094342-50-3 3-chloro-5-{[6-chloro-2-fluoro-3-({5-[4-methyl-2-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)-1,3-thiazol-5-yl]-1,3,4-oxadiazol-2-yl}methyl)phenyl]oxy}benzonitrile 
• 1094342-48-9 3-chloro-5-[(6-chloro-3-{[5-(6-{[(2S)-2,3-dihydroxy-3-methylbutyl]oxy}-2-methyl-3-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl}-2-fluorophenyl)oxy]benzonitrile 

Relevant academic research and scientific papers

4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

Synthesis, structure and stereochemistry of quinoline alkaloids from Choisya ternata

A range of seventeen quinoline alkaloids, involving several types of oxidations during their biosynthetic pathways, have been isolated from leaves of Choisya ternata. In addition to the nine known quinoline alkaloids, eight new members of the furoquinoline family, derived mainly from prenylation at C-5 (including two novel hydroperoxides), have been identified. The absolute configurations and enantiopurity values of all chiral quinoline alkaloids have been determined. One of the isolated alkaloids, 7-isopentenyloxy-γ- fagarine, has been used as a precursor for the chemical asymmetric synthesis of the enantiopure alkaloids: evoxine, anhydroevoxine and evodine. The possible roles of oxygenase and other oxygen-atom-transfer enzymes, in the biosynthetic pathways of the C. ternata alkaloids, have been discussed. This journal is The Royal Society of Chemistry.

d- and l-Serine, useful synthons for the synthesis of 24-hydroxyvitamin D3 metabolites. A formal synthesis of 1α,24R,25-(OH)3-D3, 24R,25-(OH)2-D3 and 24S,25-(OH)2-D3

d- and l-Serine have been used for the enantioselective synthesis of tosylates 7a and 7b, useful building blocks for the synthesis of triols 5a and 5b which have already been obtained via a diastereoselective synthesis and used for the synthesis of 2a, 2b and 2c. We have thus performed a formal synthesis of 24S,25-(OH)2-D3, 24R,25-(OH)2-D3 and 1α,24R,25-(OH)3-D3.

PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.

Synthesis and Determination of the Enantiomeric Pyrity of (R)- and (S)-2,3-Dihydroxy-3-methylbutyl p-Toluensulfonate

(R)- and (S)-2,3-dihydroxy-3-methylbutyl p-toluenesulfonate, used as building blocks for vitamine D3 metabolites and carotenoids, respectively, were resynthesized since differing melting points and optical rotations are reported in the literature.The give

Optically Active C5-Synthons for the Synthesis of Naturally Occurring Terpenes

The optically active synthons (S)-22, (R)-23, (R)-25 and (R)-26 were prepared from L-serine.Furthermore the tertiary alcohol 6 was synthesized from L-serine (-> (S)-6) and D-mannitol (-> (R)-6).These compounds are suitable for the synthesis of optically active natural products.